TABLE 5.
Most common related adverse eventsa
| Adverse event | No. (%) of MITT population receiving indicated treatment:
|
|
|---|---|---|
| Ceftaroline (n = 67) | Standard therapy (n = 32) | |
| Crystals in urine | 6 (9.0) | 5 (15.6) |
| Elevated level of blood creatine phosphokinase | 5 (7.5) | 2 (6.3) |
| Elevated level of alanine aminotransferase | 4 (6.0)) | 4 (12.5) |
| Elevated level of aspartate aminotransferase | 4 (6.0) | 3 (9.4) |
| Headache | 4 (6.0) | 2 (6.3) |
| Insomnia | 4 (6.0) | 2 (6.3) |
| Nausea | 4 (6.0) | 0 (0.0) |
| Rashb | 1 (1.5) | 2 (6.3) |
a
>5% in either treatment group. Infusion-associated AEs are discussed in the text.
b
Does not include one subject who reportedly had “mononucleosis syndrome” but for whom the major manifestation was a maculopapular rash.